Author

Katerina M. Antoniou

University of CreteORCID 0009-0006-0207-4582Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Dimitris Nastos· 2 shared Pantelis HatzisiD· 2 shared Paraskevi KanellopoulouiD· 2 shared Vassilis AidinisiD· 2 shared Alexios N. MatralisiD· 1 shared Antreas AfantitisiD· 1 shared Apostolos GalarisiD· 1 shared Argyrios TzouvelekisiD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

Dimitris Nastos

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

PathologybioRxivPreprintNov 12, 2025

An aerosolised dual-action Autotaxin inhibitor- PPARγ agonist for the treatment of pulmonary fibrosis

Alexios N. Matralis, Elli-Anna Stylianaki, Eleni M. Ladopoulou…·Vassilis Aidinis

This paper introduces EL244, a dual ATX inhibitor and PPARγ agonist for treating pulmonary fibrosis, showing reduced LPA levels and fibrosis in a bleomycin model.

DOI 10.1101/2025.11.12.687859

mouseexperimental assay

𝕏 PostBluesky

Molecular BiologybioRxivPreprintJan 25, 2023

SRC-mediated and TKS5-enabled podosome formation is an inherent property of IPF fibroblasts, promoting ECM invasion and pulmonary fibrosis

Ilianna Barbayianni, Paraskevi Kanellopoulou, Dionysiοs Fanidis…·Vassilis Aidinis

This study identifies TKS5-mediated podosome formation in IPF fibroblasts as a driver of ECM invasion and pulmonary fibrosis, with potential therapeutic targeting via src kinase inhibition.

DOI 10.1101/2023.01.25.522705

mousehuman

𝕏 PostBluesky